(NASDAQ: TENX) Tenax Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 83.67%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.8%.
Tenax Therapeutics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast TENX's revenue for 2028 to be $851,773,125, with the lowest TENX revenue forecast at $851,773,125, and the highest TENX revenue forecast at $851,773,125. On average, 2 Wall Street analysts forecast TENX's revenue for 2029 to be $1,060,210,938, with the lowest TENX revenue forecast at $620,043,750, and the highest TENX revenue forecast at $1,500,378,125.
In 2030, TENX is forecast to generate $1,346,831,750 in revenue, with the lowest revenue forecast at $590,113,750 and the highest revenue forecast at $2,101,943,750.